Health Canada approves generic Ozempic from Apotex, country’s largest drug maker

Apotex won Health Canada approval to sell generic semaglutide, making it the second approved generic Ozempic maker and the first with manufacturing presence in Canada. Generic competition could materially pressure Novo Nordisk’s Ozempic pricing, which currently carries a $228 four-week list price and generated $2.9 billion in Canadian sales in 2025. The drugs are expected to reach pharmacy shelves in coming weeks, with additional generic applications still pending.

Analysis

Canada is signaling a structurally faster genericization path than the market may be pricing, and that matters more for volume than near-term pricing. Once a second supplier is live, the reference price reset is enough to pull a large cohort of cash-pay and marginally insured patients into the generic channel quickly; if the third and fourth filings clear, the price step-down to 35% creates a second wave of switching rather than a linear one. The first-order hit to Novo is not just lower Canadian net price, but a likely halo effect on physician/patient expectations that the U.S. launch trajectory will eventually face the same erosion dynamic.

For RDY, the approval has optionality beyond Canada because it validates semaglutide manufacturing/regulatory capability ahead of the U.S. patent cliff. The bigger second-order winner may be any low-cost API/formulation capacity with North American distribution: local manufacturing reduces logistics friction and tender-risk, which can translate into faster pharmacy uptake and better gross-to-net retention than offshore-only peers. That said, the article’s biggest hidden variable is supply: a generic that is legally approved but constrained by fill rate or device/component bottlenecks will delay the price collapse and create a temporary winner-takes-most setup for the first mover.

The contrarian view is that the market may be overestimating how quickly Novo’s Canadian revenue decays. Prescriptions can stay sticky if reimbursement rules, pharmacy stocking practices, and patient inertia slow the switch, so the revenue hit may be more of a gradual 2-4 quarter bleed than an immediate cliff. The real risk to the short NVO is if management offsets Canadian erosion with stronger U.S. obesity demand and pricing discipline elsewhere, making Canada more of a sentiment event than an earnings event.

Catalyst timing is near-term: pharmacy shelf placement, generic supply availability, and any third/fourth approvals over the next 1-3 months will determine whether this becomes a step-down or a slow grind. If additional approvals arrive, the pricing framework mechanically forces deeper discounting and should accelerate volume migration; if not, the current economics may prove less disruptive than the headline suggests.

Key Decisions for Investors

• Short NVO on any post-approval strength, with a 1-3 month horizon; thesis is margin compression in Canada plus negative read-through on broader semaglutide pricing power. Cover if management signals limited Canadian revenue exposure or if generic supply proves too thin to move volumes.
• Long RDY versus short NVO as a pairs trade over the next 3-6 months; RDY gains regulatory optionality while NVO faces brand erosion. Keep sizing modest because the first mover advantage can fade once additional generics arrive.
• Buy RDY call spreads or outright calls into the next 4-8 weeks if implied vol remains below event risk; upside is tied to follow-on approvals and commercialization evidence, while downside is cushioned by the existing FDA optionality.
• Avoid chasing Canadian pharmacy names or distributors until fill-rate data confirms actual generic take-up; the early trade may be headline-driven but real earnings impact depends on inventory turn and reimbursement execution.
• If NVO sells off sharply on the headline, consider a tactical long only if the move implies immediate Canadian revenue destruction; the more likely path is a slower 2-4 quarter decay, which makes panic selling attractive for mean reversion.